Inflammation as a central driver in AML pathogenesis and therapy resistance
- 9 October 2026
- journal article
- review article
- Published by Springer Nature in Science China Life Sciences
- p. 1-20
Abstract
Inflammation is a prominent feature of the bone marrow microenvironment in acute myeloid leukemia and contributes to leukemic evolution, progression, and therapeutic resistance. Accumulating evidence indicates that inflammatory signals in AML arise from multiple sources, including age-associated inflammaging, mutation-driven pathways, cell-intrinsic stress programs, and external inflammatory stimuli such as infections. These signals collectively facilitate the progression from clonal hematopoiesis and other pre-leukemic states to overt leukemia and support malignant expansion. Leukemic blasts, immune effector and regulatory cells, mesenchymal stromal cells, and endothelial cells collectively establish an inflammatory niche through the production of cytokines and chemokines. This niche supports leukemic stem cell maintenance and fitness, promotes metabolic adaptation and survival, and disrupts normal hematopoiesis and immune surveillance. The inflammatory microenvironment can also compromise therapeutic efficacy by inducing drug tolerance, reinforcing protective bone marrow niches, and reshaping responses to chemotherapy, targeted therapies, immunotherapies, and transplantation-associated graft-versus-leukemia effects. Although increasing mechanistic insights have inspired strategies aimed at neutralizing inflammatory mediators, blocking downstream signaling pathways, or reprogramming the microenvironment to restore anti-leukemic immunity, such anti-inflammatory approaches remain incompletely explored in clinical practice. A deeper understanding of cell type-specific inflammatory circuits and cytokine interactions will be essential for developing rational combination therapies to overcome microenvironment-driven resistance.Keywords
This publication has 243 references indexed in Scilit:
- Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and ManagementAmerican Journal of Hematology, 2025
- Acute Myeloid Leukemia Cells Educate Mesenchymal Stromal Cells toward an Adipogenic Differentiation Propensity with Leukemia Promotion CapabilitiesAdvanced Science, 2022
- Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T‐cells and regulatory T‐cells in TP53‐mutated acute myeloid leukemiaCancer Medicine, 2022
- De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017Cancer, 2021
- CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AMLMolecular Oncology, 2020
- Interleukin (IL)‐33: an orchestrator of immunity from host defence to tissue homeostasisClinical & Translational Immunology, 2020
- Regulatory T cells‐derived IL‐35 promotes the growth of adult acute myeloid leukemia blastsInternational Journal of Cancer, 2015
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJAMA, 2009
- Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blastsInternational Journal of Cancer, 2006
- Interleukin (IL)-15 induces survival and proliferation of the growth factor-dependent acute myeloid leukemia M-07e through the IL-2 receptor β/γInternational Journal of Cancer, 1998